GRIFOLS, S.A. | Sequential Page Number | ||
| 1.Other Relevant Information, dated June 30, 2021 | 3 |
Grifols, S.A.
Avinguda de la Generalitat 152-158 Tel. [34] 935 710 500 Fax [34] 935 710 267 www.grifols.com |
Pursuant to the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ('Grifols') hereby informs about the following
OTHER RELEVANT INFORMATION
Grifols informs that it has signed a corporate transaction by means of which GIC, the sovereign wealth fund of Singapore, have entered into a definitive agreement under which GIC will invest approx. US$1 Bn in Grifols' wholly-owned US subsidiary Biomat USA, Inc. ('Biomat'). In exchange, GIC will acquire a minority stake in Biomat, in the form of newly issued preferred non-voting stock.
Biomat (together with its subsidiaries) holds a plasma collection business with 296 plasma collection centers throughout the territory of the United States.
Grifols will continue to control all aspects of the day-to-day management of Biomat and, through a long-term plasma supply agreement, all plasma collected by Biomat and its subsidiaries will continue to be supplied to Grifols for the further manufacturing of plasma derived products.
Grifols will apply all proceeds from GIC's investment to repay debt
The consummation of GIC's strategic investment in Grifols is subject to certain closing conditions, including the obtainment of applicable regulatory authorizations, such as the Committee on Foreign Investments in the United States (CFIUS).
In Barcelona, on 30 June 2021
| Nuria Martín Barnés | |
| Secretary to the Board of Directors |
Attachments
- Original document
- Permalink
Disclaimer
Grifols SA published this content on 30 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 June 2021 11:36:05 UTC.
